However, using a cell-free biochemical binding assay, ZLc002 failed to disrupt the in vitro binding between His-neuronal nitric oxide synthase<sub>1-299</sub> and glutathione S-transferase-NOS1AP<sub>400-506</sub>, protein sequences containing the required binding domains for this protein-protein interaction, suggesting an indirect mode of action in intact cells.ZLc002 (4-10 mg/kg i.p.) suppressed formalin-evoked inflammatory pain in rats and reduced Fos protein-like immunoreactivity in the lumbar spinal dorsal horn.